<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and B-lineage <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells and IL-3 and IL-7 for ALL cells </plain></SENT>
<SENT sid="1" pm="."><plain>Each molecule was added daily and cell proliferation was evaluated on day 3 by <z:chebi fb="0" ids="17748">thymidine</z:chebi> incorporation </plain></SENT>
<SENT sid="2" pm="."><plain>Whereas TGFbeta was found inhibitory in <z:hpo ids='HP_0000001'>all</z:hpo> the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cases studied, MIP1alpha was inhibitory in 6/12 AML cases and had no effect on <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>AcSDKP and Tbeta4 showed an inhibitory effect in a few cases but only at high doses which were inactive on <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, our study not only confirms the effect of TGFbeta, MIP1alpha and AcSDKP on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells but also provides new data concerning their effect on <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and the possible inhibitory effect of AcSDKP at high doses </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, we show for the first time the effect of Tbeta4 on leukemic cells </plain></SENT>
<SENT sid="6" pm="."><plain>Altogether, our data indicate differences of sensitivity of leukemic cells to negative regulators, some <z:hpo ids='HP_0001909'>leukemias</z:hpo> being inhibited by one or several of these molecules whereas others were unresponsive to <z:hpo ids='HP_0000001'>all</z:hpo> used </plain></SENT>
<SENT sid="7" pm="."><plain>The clinical relevance of these observations still remains to be determined </plain></SENT>
</text></document>